ImmunoGen Inc. agreed to license some of its compounds to Sanofi for a $30 million payment.
The compounds were developed by Sanofi using ImmunoGen's technology. They are five in total: SAR650984, SAR566658, SAR408701 and SAR428926 for the treatment of certain types of tumors, including triple negative breast cancer, and an antibody-drug conjugate being directed to an undisclosed target.
ImmunoGen also agreed to forgo future milestone and royalty payments in exchange for the payment.